Brian Drachman

Penn Presbyterian Medical Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index6.7kcitations67works22.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(56), Parathyroid Disorders and Treatments(19), Eosinophilic Disorders and Syndromes(12), Peptidase Inhibition and Analysis(8), Coagulation, Bradykinin, Polyphosphates, and Angioedema(7)

Publications66 total

Abstract 4363872: Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Circulation·2025
Renal responses in a phase 1/2 study of at-02, a novel pan-amyloid depleter ig fusion protein for the treatment of patients with AL amyloidosis
Blood·2025Open Access
Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy
JACC Advances·2025Open Access
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS
Cardiology and Therapy·2025· 1 citedOpen Access
Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary
Future Cardiology·2025Open Access
Principaux résultats d’HELIOS-B, étude de phase 3 évaluant le vutrisiran chez les patients atteints d’amylose à transthyrétine avec cardiomyopathie
La Revue de Médecine Interne·2024
Abstract 4146737: AmyNet: a Novel Deep Learning Imaging Approach to Identify Incidental Myocardial Uptake Indicative of Cardiac Amyloidosis on Whole Body 99Tc-Bone Scintigraphy Imaging
Circulation·2024· 1 cited
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
European Heart Journal·2024Open Access
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
New England Journal of Medicine·2024· 286 citedOpen Access
Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis
JACC Advances·2024· 10 citedOpen Access
Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction
European Journal of Heart Failure·2024· 9 citedOpen Access
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Journal of Cardiac Failure·2024· 32 citedOpen Access
Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis PC143 (#519)
2024
Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC149 (#8)
2024· 1 cited
Deep learning approach for automated segmentation of myocardium using bone scintigraphy single-photon emission computed tomography/computed tomography in patients with suspected cardiac amyloidosis
Journal of Nuclear Cardiology·2024· 14 cited
Baseline Characteristics Of Patients With Transthyretin Cardiac Amyloidosis Enrolled In The Patisiran Expanded Access Program
Journal of Cardiac Failure·2024
Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: Post-hoc analysis of the APOLLO-B study
Archives of cardiovascular diseases·2023
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
Cardiology and Therapy·2023· 18 citedOpen Access
Abstract 13273: APOLLO-B, a Study of Patisiran in Patients With Transthyretin Cardiac Amyloidosis: Primary Long-Term Results From the Open-Label Extension Period
Circulation·2023· 6 cited
Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study
European Heart Journal·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Márcia Waddington‐Cruz(19), Teresa Coelho(16), Mathew S. Maurer(16), Arnt V. Kristen(15), Violaine Planté‐Bordeneuve(15), Giampaolo Merlini(14), Michael Polydefkis(14), Martha Grogan(13), Isabel Conceição(13), Daniel J. Lenihan(13), Stephen S. Gottlieb(13), Sanjiv J. Shah(12), David Adams(12), Ronald Witteles(11), Thibaud Damy(11), John L. Berk(11), Angela Dispenzieri(11), Scott L. Hummel(11), Leslie Amass(11), Mazen Hanna(10)